Page 34 - IJB-9-6

International

Journal of Bioprinting

RESEARCH ARTICLE
Printed cisplatin on microneedle arrays for

transdermal delivery enhances olaparib-
induced synthetic lethality in a mouse model of

homologous recombination deficiency

Zoi Kanaki , Alexandra Smina , Chrysoula Chandrinou ,
2
1
1
Fotini E. Koukouzeli , Yiannis Ntounias , Nikolaos Paschalidis , Ilias Cheliotis ,
1
2
1
1
Marina Makrygianni , Jill Ziesmer , Georgios A. Sotiriou , Ioanna Zergioti ,
3
2
3
2
Constantin Tamvakopoulos , and Apostolos Klinakis *
1
1
1 Biomedical Research Foundation Academy of Athens, 4 Soranou Efessiou Street, 11527 Athens,
Greece
2 Department of Physics, School of Mathematical and Physical Sciences, National Technical
University of Athens, Heroon Polytehneiou 9, 15780 Athens, Greece
3
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm,
Sweden
(This article belongs to the Special Issue: Laser bioprinting technologies)
Abstract
Small molecule inhibitors targeting specific proteins are claiming a continuously
growing share in cancer therapy, more commonly in combination with traditional
chemotherapeutic drugs. While these inhibitors are taken orally, the majority of
*Corresponding author: chemotherapies are administered through intravenous injection in the hospital
Apostolos Klinakis premises. Alternative routes for chemotherapy administration would allow more
(aklinakis@bioacademy.gr)
frequent administration at lower dosing by the patient oneself, allowing combination
Citation: Kanaki Z, Smina A, treatment with reduced side effects. Here, we employed laser printing to prepare
Chandrinou C, et al., 2023, Printed
cisplatin on microneedle arrays microneedles for transdermal delivery of cisplatin. Combination treatment with
for transdermal delivery enhances cisplatin transdermally and the poly (ADP-ribose) polymerase (PARP) inhibitor
olaparib-induced synthetic lethality olaparib orally leads to effective treatment in a cancer xenograft mouse model
in a mouse model of homologous
recombination deficiency. in vivo, while reducing the risk for systemic side effects. This work opens new avenues
Int J Bioprint, 9(6): 0048. in anti-cancer therapy by allowing the administration of chemotherapy without the
https://doi.org/10.36922/ijb.0048 need for intravenous injection alone or in combination with other therapies.
Received: February 10, 2023
Accepted: March 23, 2023
Published Online: June 23, 2023 Keywords: Laser-induced forward transfer; Microneedles; Metronomic
chemotherapy; Transdermal dosing; Synthetic lethality; Homologous
Copyright: © 2023 Author(s).
This is an Open Access article recombination deficiency
distributed under the terms of the
Creative Commons Attribution
License, permitting distribution,
and reproduction in any medium, 1. Introduction
provided the original work is
properly cited. Chemotherapy has been the cornerstone of anti-cancer therapy for several decades now.
Publisher’s Note: AccScience More recently, advances in next-generation sequencing allowed the identification of
Publishing remains neutral with several actionable mutations which can be exploited therapeutically toward personalized
regard to jurisdictional claims in approaches in cancer treatment . Novel targeted therapies such as small molecules and
[1]
published maps and institutional
affiliations. antibodies that emerged after the 2000s showed great promise and were approved for

Volume 9 Issue 6 (2023) 26 https://doi.org/10.36922/ijb.0048